{
    "ticker": "ESPR",
    "name": "Esperion Therapeutics, Inc.",
    "description": "Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for patients with elevated cholesterol levels and cardiovascular disease. Founded in 2008 and headquartered in Ann Arbor, Michigan, Esperion is dedicated to transforming the treatment landscape of lipid management through its proprietary oral therapies. The company's lead product, Nexletol (bempedoic acid), is designed to lower LDL-C (low-density lipoprotein cholesterol) levels in patients who are unable to reach their cholesterol goals on their current medications. Esperion's mission is to provide patients with effective treatment options that can deliver significant cardiovascular benefits while being well-tolerated. The company is committed to scientific excellence and leverages extensive clinical research to develop its therapies, which aim to fill unmet medical needs in the cardiovascular space. In addition to Nexletol, Esperion is actively working on developing additional pipeline candidates that address various aspects of lipid management and cardiovascular health. With a focus on patient-centric approaches and innovative science, Esperion is poised to make a meaningful impact in the lives of patients at risk of cardiovascular events.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Ann Arbor, Michigan, USA",
    "founded": "2008",
    "website": "https://www.esperion.com",
    "ceo": "Eric S. A. S. W. R. J. A. M. R. W. H. A. P. A. H. D. D. K. D. R. E. M. M. H. J.",
    "social_media": {
        "twitter": "https://twitter.com/Esperion"
    },
    "investor_relations": "https://investors.esperion.com",
    "key_executives": [
        {
            "name": "Eric S. A. S. W. R. J. A. M. R. W. H. A. P. A. H. D. D. K. D. R. E. M. M. H. J.",
            "position": "CEO"
        },
        {
            "name": "Sharon M. D. M.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cardiovascular Drugs",
            "products": [
                "Nexletol (bempedoic acid)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Esperion Therapeutics, Inc. | Innovative Cardiovascular Treatments",
        "meta_description": "Explore Esperion Therapeutics, Inc., a leader in developing innovative therapies for managing elevated cholesterol and cardiovascular disease. Discover their commitment to improving patient outcomes.",
        "keywords": [
            "Esperion",
            "Cardiovascular Drugs",
            "Cholesterol Management",
            "Nexletol",
            "Bempedoic Acid",
            "Lipid Management"
        ]
    },
    "faq": [
        {
            "question": "What is Esperion known for?",
            "answer": "Esperion is known for developing innovative treatments for patients with elevated cholesterol levels and cardiovascular disease, particularly its drug Nexletol."
        },
        {
            "question": "Who is the CEO of Esperion?",
            "answer": "Eric S. A. S. W. R. J. A. M. R. W. H. A. P. A. H. D. D. K. D. R. E. M. M. H. J. is the CEO of Esperion Therapeutics, Inc."
        },
        {
            "question": "Where is Esperion headquartered?",
            "answer": "Esperion is headquartered in Ann Arbor, Michigan, USA."
        },
        {
            "question": "What is Esperion's main product?",
            "answer": "Esperion's main product is Nexletol (bempedoic acid), which is used to lower LDL cholesterol levels."
        },
        {
            "question": "When was Esperion founded?",
            "answer": "Esperion was founded in 2008."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "PFE",
        "ABBV"
    ],
    "related_stocks": [
        "JNJ",
        "MRK",
        "BMY",
        "GILD"
    ]
}